全部照片(1)
About This Item
經驗公式（希爾表示法）:
C15H22FN3O6
CAS號碼:
分子量：:
359.35
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
暫時無法取得訂價和供貨情況
推薦產品
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D +80 to +100°, c = 0.5 in methanol
顏色
white to beige
溶解度
H2O: 10 mg/mL, clear (warmed)
儲存溫度
2-8°C
SMILES 字串
O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C
InChI
1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
InChI 密鑰
GAGWJHPBXLXJQN-UORFTKCHSA-N
基因資訊
human ... TYMS(7298)
尋找類似的產品？ 前往 產品比較指南
應用
Capecitabine has been used:
- in combination with gemcitabine to achieve glutamine deprivation by enhancing the sensitivity of expression in pancreatic ductal adenocarcinoma (PDAC) cells to inhibitors of glutamine metabolism and study its effect on PDAC cell survival[1]
- to study the drug metabolic function in a two-organ microfluidic system[2]
- as an anti-cancer agent to study its cytotoxic activity alone or in combination with B87 on cancer cells[3]
生化／生理作用
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。 卡培他滨的激活遵循具有三个酶促步骤和两个中间代谢物5′-脱氧-5-氟胞苷（5′-DFCR）和5′-脱氧-5-氟尿苷（5′-DFUR）的途径，形成5-氟尿嘧啶。
訊號詞
Danger
危險聲明
危險分類
Carc. 1B - Muta. 2 - Repr. 1B
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
分析證明 (COA)
Lot/Batch Number
客戶也查看了
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Tim Meyer et al.
European journal of cancer (Oxford, England : 1990), 50(5), 902-911 (2014-01-22)
Cytotoxic chemotherapy is widely used for advanced, unresectable pancreatic and other gastrointestinal foregut neuroendocrine tumours (NETs) and the most commonly used regimen combines 5-fluorouracil with streptozocin. The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an
Mitsuhiro Tomoda et al.
Anticancer research, 34(1), 191-194 (2014-01-10)
Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy. In the present study, we administered monthly chemotherapy and aimed to evaluate the usefulness of the specific treatment schedule in patients with
Valentina Sini et al.
Tumori, 99(6), 273e-277e (2014-02-08)
This report describes a case of ab initio metastatic HER2-positive breast cancer in a very young patient. The onset of breast cancer at such a young age is uncommon and could delay the diagnosis with unquestionable impact on the prognosis.
Ferdinando Riccardi et al.
Tumori, 99(6), 257e-260e (2014-02-08)
Targeted therapies against HER2 (trastuzumab, lapatinib) have improved the efficacy of treatment and the outcome of patients with HER2-positive breast cancer. Lapatinib is a tyrosine kinase inhibitor targeting EGFR1 and HER2: it binds the intracellular domain of these receptors and
Sofia Palacio et al.
Anticancer research, 34(1), 301-306 (2014-01-10)
There is no standard chemotherapy regimen that is universally accepted for the treatment of advanced gastric cancer. Trastuzumab added to chemotherapy improves survival in patients with metastatic human epidermal growth factor receptor-2 (Her2/neu)-overexpressing gastric cancer. Data are lacking for the
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
